1. In Vivo

Five (Non-COVID) Clinical Trial Hits Of 2021

 
• By Alexandra Shimmings

2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.

Hit the target
• Source: Alamy

The detailed results in August of Boehringer Ingelheim GmbH and Eli Lilly and Company's closely watched EMPEROR-Preserved trial of Jardiance were hailed as ground-breaking after its investigators said the SGLT2 inhibitor was the first drug to show "unequivocal benefit" on major harmful outcomes in patients with heart failure and a preserved ejection fraction (HFpEF).

Data from the 5,988-patient study, the highlight of the virtual European Society of Cardiology meeting, showed that Jardiance (empagliflozin) plus...

More from Innovation

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.